Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31322962 | 0.92 | ALDH1A1 (0.34) | GAAKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL22207434 | 0.84 | CYP1A2 (0.35) | ABL1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL18421834 | 0.83 | ALDH1A1 (0.33) | GAAABL1KMT2AMAPTMEN1 | |
| SCHEMBL22236183 | 0.83 | MEN1 (0.41) | ABL1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL30079004 | 0.82 | ALDH1A1 (0.39) | GAAABL1KMT2AMAPTMEN1 | |
| SCHEMBL3934630 | 0.82 | ALDH1A1 (0.32) | GAAABL1KMT2AMAPTMEN1 | |
| SCHEMBL21854406 | 0.81 | CYP1A2 (0.33) | ABL1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL2804353 | 0.81 | HCAR3 (0.38) | ABL1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL5578038 | 0.81 | HCAR3 (0.33) | ABL1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3576511 | 0.80 | ALDH1A1 (0.40) | GAAABL1KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218290-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218285-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218288-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| CN-118251397-A | LRRK2 inhibitors | H.隆德贝克有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023073013-A9 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-08-17 | — | — | WO | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| WO-2023073013-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-04 | — | — | WO | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3652179-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-05-20 | — | — | EP | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | GAA 2883/4885ABL1 445/4885KMT2A 1492/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | GAA 331/4885ABL1 473/4885KMT2A 1900/4885 |
| US-11780851-B2 | LRRK2 inhibitors | LRRK2, PARK7, PINK1 | GAA 90/4885ABL1 250/4885KMT2A 1578/4885 |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | GAA 438/4885ABL1 1454/4885KMT2A 2310/4885 |
| US-20230144725-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | GAA 90/4885ABL1 250/4885KMT2A 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.